{"analyses":[{"ciLowerLimit":"-2.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"33.0","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0002","pValueComment":"P-value was stratified by baseline disease diagnosis (pcALCL and MF).","paramType":"Risk Difference (RD)","paramValue":"15.6","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.9","upperLimit":"26.4","value":"17.2"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"8.4","value":"1.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"description":"Complete Response (CR) was determined by the IRF based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG000","title":"Brentuximab Vedotin"},{"description":"Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\\^2, tablets, orally, once daily with meals for up to 48 weeks.","id":"OG001","title":"Methotrexate or Bexarotene"}],"paramType":"NUMBER","populationDescription":"The ITT population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment.","reportingStatus":"POSTED","timeFrame":"Each Cycle until disease progression, death or data cutoff (Median overall follow-up 38.8 months)","title":"Percentage of Participants Achieving a CR","type":"SECONDARY","unitOfMeasure":"percentage of participants"}